Astellas walks away from $450M+ Cytokinetics pact after taking a few extra months to see progress
Months after losing longtime partner Amgen on its lead heart drug, Cytokinetics is waving goodbye to another ally — and with it, more than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
